LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

Search

Aldeyra Therapeutics Inc

Chiusa

2.65 8.16

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

2.44

Massimo

2.66

Metriche Chiave

By Trading Economics

Entrata

5.9M

-9.9M

EPS

-0.17

Margine di Profitto

-6,465.066

Dipendenti

8

EBITDA

5.9M

-9.4M

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+280.82% upside

Dividendi

By Dow Jones

Utili prossimi

30 lug 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

-5M

127M

Apertura precedente

-5.51

Chiusura precedente

2.65

Punteggio Tecnico

By Trading Central

Fiducia

Very Strong Bearish Evidence

Aldeyra Therapeutics Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

3 apr 2025, 22:40 UTC

I principali Market Mover

Aldeyra Shares Fall on FDA Complete Response Letter for Dry Eye Disease Drug

18 nov 2024, 20:20 UTC

I principali Market Mover

Aldeyra Therapeutics Shares Up, FDA to Review New Drug Application

Confronto tra pari

Modifica del prezzo

Aldeyra Therapeutics Inc Previsione

Obiettivo di Prezzo

By TipRanks

280.82% in crescita

Previsioni per 12 mesi

Media 9.33 USD  280.82%

Alto 11 USD

Basso 6 USD

Basato su 6 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Aldeyra Therapeutics Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

6 ratings

6

Acquista

0

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

1.9 / 2.65Supporto e resistenza

A breve termine

Very Strong Bearish Evidence

A termine intermedio

Very Strong Bearish Evidence

A lungo termine

Strong Bearish Evidence

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Aldeyra Therapeutics Inc

Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases. The company also develops ADX-629, an orally administered RASP modulator for treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment retinitis pigmentosa, as well as rare retinal diseases characterized by inflammation and vision loss. In addition, it develops ADX-246 in systemic immune-mediated disease; and ADX-248 in geographic atrophy. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.